scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2022 Earnings Call Transcript

Naz Rahman: Now these 10 payers and the 85% of the lives, do you expect to actually have coverage for them initially at launch in January? Or do you think they’ll trickle in like through 1Q?

Steve Parsons: I think it’ll take until the end of 1Q, just based on when they have P&T committee meetings. We’re fortunate that we’re getting a few done with some big ones in November and December, but there’s others that will take until their normally scheduled meeting in Q1, which could be January or February. I think the latest we’d have to wait would be March. But Q1, for sure, we’ll have had all of the meetings scheduled, reviews conducted and decisions made. And as I said, we expect them to be universally positive. It’ll be surprising to us, very surprising if anyone makes a decision not to cover FUROSCIX.

Operator: Ladies and gentlemen, we have reached the end of the question-and-answer session. I would now like to hand the call back to John Tucker for any closing comments. Please go ahead, sir.

John Tucker: Thank you. That concludes our call for this afternoon. We hope we were successful in conveying our enthusiasm for FUROSCIX following its approval and the significant advancement that it represents along the heart failure treatment paradigm, a multibillion dollar market in the U.S. alone. We are well financed, and we will be initiating what we think is a very robust commercial launch in the coming months. Thank you again for joining our call this afternoon. Have a great evening.

Operator: That concludes today’s conference. Thank you for joining us. You may now disconnect your lines.